



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade: 2.24

Trade Time: 12:38 PM ET  
05/21/18

Change: -0.14 ↓  
(5.882%)

Day Range 2.22 - 2.38

52-Week Range 1.42 - 4.37

Volume 214,963

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

05/15/18

[Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage](#)

05/07/18

[Rexahn Reports First Quarter 2018 Financial Results](#)

04/26/18

[Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

03/13/18

[Rexahn Pharmaceuticals to Present at Two Upcoming Conferences](#)

03/12/18

[Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

03/09/18

[Annual Report \(10-K\)](#)

04/23/18

[Proxy Statement \(DEF 14A\)](#)

05/04/18

[Quarterly Report \(10-Q\)](#)

11/03/17

[Quarterly Report \(10-Q\)](#)

08/04/17

[Quarterly Report \(10-Q\)](#)